Our Broad and Disruptive Platform
We are delivering a new class of RNA therapies – Antibody Oligonucleotide Conjugates (AOCs). AOCs overcome current barriers to the delivery of oligonucleotides unlocking their potential to treat diseases currently lacking adequate treatment options and allowing us to address unmet patient needs. We have demonstrated preclinical proof of concept for AOCs in multiple tissues. We are broadening our research to other tissue and cell types through internal discovery efforts and partnerships.